Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2024-06-03 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物自愿披露关于公司通过药品GMP符合性检查的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a company about passing a GMP compliance inspection by a regulatory authority (Jiangsu Provincial Drug Administration). It describes the inspection results, product details, and impact on production capacity and company operations. The document is short (1360 characters) and does not contain financial statements or detailed financial data. It is an official announcement about regulatory compliance and operational status rather than a full report or financial filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-06-03 Chinese
中信证券股份有限公司关于前沿生物药业（南京）股份有限公司2023年年报问询函回复的核查意见
Annual Report Classification · 95% confidence The document is a detailed response from a securities company (中信证券股份有限公司) regarding inquiries about the 2023 annual report of 前沿生物药业（南京）股份有限公司. It discusses various aspects of the company's 2023 annual report, including business operations, revenue recognition, inventory valuation, and profitability. The text references the 2023 annual report multiple times and provides detailed financial data and management explanations related to that fiscal year. The document is lengthy (15,000 characters) and contains substantive financial and operational analysis, not merely an announcement or certification. Therefore, it is the actual annual report or a detailed report closely tied to the annual report content. Given the content and context, the filing type is Annual Report (10-K). FY 2023
2024-04-30 Chinese
中审众环会计师事务所（特殊普通合伙）关于前沿生物药业(南京)股份有限公司2023年年度报告的信息披露监管问询函的专项审核报告
Audit Report / Information Classification · 92% confidence The document is titled a “专项审核报告” (“special audit report”) by Zhongshenzhonghuan Certified Public Accountants responding to an information disclosure regulatory inquiry letter from the Shanghai Stock Exchange concerning the company’s 2023 Annual Report. It contains the auditor’s review procedures and audit opinions rather than the full annual report itself. This aligns with a standalone audit report or audit information filing, matching the AR category. FY 2023
2024-04-30 Chinese
前沿生物关于2023年年度报告的信息披露监管问询函的回复公告
Annual Report Classification · 95% confidence The document is a detailed response to a regulatory inquiry regarding the company's 2023 annual report. It includes extensive financial data, operational details, risk disclosures, and auditor and sponsor opinions related to the annual report. The content focuses on clarifications about revenue recognition, production changes, business expansion, inventory valuation, and profitability trends for the fiscal year 2023. The presence of detailed financial figures, audit opinions, and comprehensive management explanations indicates this is part of the Annual Report or closely related to it. The document is lengthy (15,000 characters) and contains substantive financial and operational information, not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-04-30 Chinese
前沿生物2024年第一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '2024 年第一季度报告' which translates to '2024 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2024. The report explicitly states it is unaudited and covers a period shorter than a full fiscal year (a quarter). The presence of comprehensive financial statements and analysis for a quarterly period aligns with the definition of an Interim / Quarterly Report (IR). The document length is over 13,000 characters, indicating it is the full report, not just an announcement or summary. Therefore, the correct classification is IR with high confidence. Q1 2024
2024-04-25 Chinese
国浩律师（南京）事务所关于前沿生物药业（南京）股份有限公司2023年年度股东大会的法律意见书
Regulatory Filings Classification · 90% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm concerning the convening, procedures, attendance, agenda and voting results of the company’s 2023 Annual General Meeting. It is not the annual report itself, nor an investor presentation or earnings release. It is essentially a certification/attestation by legal counsel. Under the CERTIFICATION RULE, a lawyer’s opinion letter—even though it includes vote tallies—should be classified as a Regulatory Filing (RNS).
2024-04-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.